ADCytherix
Biotechnology
$113.4Mlatest round · Series A · Oct 2025 · 12 mo ago
5backers · RA Capital Management, aMoon
50+team · employees, estimated range
13stories in the press
Overview
Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer. The company was founded by the previous founders of Emergence Therapeutics.
Funding and backers
Total raised
$113.4M
1 round on record
Latest round
$113.4M
Series A · Oct 2025 · 12 mo ago
Team
51-200
employees, estimated range
Backers
5
RA Capital Management, aMoon
The money's age
Due for its next round
12 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 16, 2025
Raised a round Series A $113.4M · The Manila Times
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | Oct 2025 | $113.4M | — | The Manila Times |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
At Oxford BioTherapeutics, we are dedicated to pioneering the next generation of oncology treatments through targeted therapies, including…
THE CLAUDIN-1 COMPANY Treat cancer and reverse fibrosis We are a clinical-stage biotech company with a mission to treat cancer and reverse…
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality.
SystImmune is a clinical-stage biopharmaceutical company in Redmond, Washington, that develops cancer drugs, including bispecific…
Novel ADC Payloads for Cancer Hexagon Bio is developing novel payload mechanisms for antibody-drug conjugates (ADCs) to overcome resistance…
First-in-class ADCs tailored to attack advanced cancer.. Ona Therapeutics is pioneering the development of first-in-class antibody drug…
Financials
Total raised
$113.4M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2025 | $113.4M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Angelini VenturesVia a fund
aMoonVia a fund
PontifaxVia a fund
55 portfolio companies: Climb Bio, CadenSee, Crystalys Therapeutics - Passionate. Dedicated. We improve lives. and 52 more
Kurma PartnersVia a fund
RA Capital ManagementVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth
Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth
Read more
Report
Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth
Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth Initial patient dosed in the First-in-Human clinical trial of ADCX-020, marking Adcytherix's transition into a clinical-stage company wi
Read more
Report
Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth
Initial patient dosed in the First-in-Human clinical trial of ADCX-020, marking Adcytherix's transition into a clinical-stage company within its second year of operations.
Read more
Report
Adcytherix Doses First Patient In Phase 1 Trial Of ADCX-020 And Strengthens Leadership To Support Next Phase Of Growth
Read more
Report
Adcytherix Powers Ahead: Technology and Team in Place to Deliver Strategy and Build an ADC Powerhouse
Adcytherix Powers Ahead: Technology and Team in Place to Deliver Strategy and Build an ADC Powerhouse Adcytherix reinforces its Executive Committee with two pivotal appointments: CMO and CFOThe ADCX - Engine is operational to start driving execution Marse
Read more
Report
Adcytherix Powers Ahead: Technology and Team in Place to Deliver Strategy and Build an ADC Powerhouse
Adcytherix reinforces its Executive Committee with two pivotal appointments: CMO and CFO. The ADCX - Engine is operational to start driving execution.
Read more
Report
Adcytherix Powers Ahead: Technology and Team in Place to Deliver Strategy and Build an ADC Powerhouse
Read more
Report
Adcytherix: €105 Million Series A Raised For Advancing Antibody-Drug Conjugate Pipeline And Novel Payload Platform
Adcytherix, a biopharmaceutical company pioneering the design and development of novel antibody-drug conjugates (ADCs), announced the completion of a €105 million (US$122 million) Series A financing round. The funding will accelerate the company's lead cl
Read more
Report
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads
October 16, 2025 Financing led by Bpifrance with co-leads Kurma Partners, Andera Partners and Angelini Ventures, followed by other prestigious new investors, Surveyor Capital (a Citadel company) and aMoon, and with renewed participation from all existing
Read more
Report
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads
Read more
Report
Show more news